Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation

Objective In clonal animal cells, certain angiotensin receptor blockers (ARB) activate the peroxisome proliferator-activated receptor-γ (PPARγ). The aim of this work was to validate that observation in human cells and humans. Methods We investigated the induction of in-vitro adipogenesis and the activation of PPARγ-target genes, adiponectin and lipoprotein lipase, by ARB in human preadipocytes. We also studied PPARγ response-element-driven luciferase reporter gene activation in human adipocytes. Finally, we treated 14 obese men for 10 days with placebo crossed over with 150 mg/day irbesartan. Subcutaneous fat was analyzed for mRNA expression of adiponectin and lipoprotein lipase. Results Telmisartan and irbesartan, and to a lesser degree losartan, induced adipogenesis and activated PPARγ-target genes. This stimulation of PPARγ-target genes was prevented by the PPARγ antagonist GW9662. Eprosartan had no effect. Paradoxically, all ARB activated the luciferase reporter gene. PPARγ activity increased approximately two-fold with pioglitazone and 1.5-fold with the ARB in all assays. In the cross-over clinical study, irbesartan lowered blood pressure but had no effect on adiponectin or lipoprotein lipase mRNA expression. Conclusions Our data are the first to show that ARB induce adipogenesis and PPARγ-target gene expression in human adipocytes. Pharmacokinetic differences may contribute to the heterogeneous effects on metabolism and preadipocyte differentiation. In humans, larger doses of ARB, longer treatments, or both may be required to activate PPARγ in adipose cells.

[1]  C. Kahn,et al.  Crosstalk between insulin and angiotensin II signalling systems. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  U. Kintscher,et al.  Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. , 2005, Diabetes.

[3]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[4]  Y. Hattori,et al.  RETRACTED ARTICLE: Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats , 2005, Diabetologia.

[5]  H. Lodish,et al.  The role of the adipocyte hormone adiponectin in cardiovascular disease. , 2005, Current opinion in pharmacology.

[6]  K. Çağlar,et al.  Blockade of the Renin-Angiotensin System Increases Plasma Adiponectin Levels in Type-2 Diabetic Patients with Proteinuria , 2005, Nephron Clinical Practice.

[7]  A. Scheen,et al.  Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. , 2004, Diabetes & metabolism.

[8]  K. Nakao,et al.  An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3‐L1 adipocytes , 2004, FEBS letters.

[9]  K. Shimamoto,et al.  Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. , 2004, Journal of hypertension.

[10]  Y. Miyazaki,et al.  Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  P. Strålfors,et al.  Expression of a mutant IRS inhibits metabolic and mitogenic signalling of insulin in human adipocytes , 2004, Molecular and Cellular Endocrinology.

[12]  U. Kintscher,et al.  Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity , 2004, Circulation.

[13]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[14]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[15]  S. Smith.  Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. , 2003, Biochimie.

[16]  K. Shimamoto,et al.  Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension , 2003, Hypertension.

[17]  Arya M. Sharma,et al.  The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? , 2003, The international journal of biochemistry & cell biology.

[18]  Arya M. Sharma,et al.  Association between adiponectin and mediators of inflammation in obese women. , 2003, Diabetes.

[19]  S. Mudaliar,et al.  Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. , 2003, Diabetes.

[20]  Arya M. Sharma,et al.  Tissue-Specific Response to Interstitial Angiotensin II in Humans , 2003, Hypertension.

[21]  Arya M. Sharma,et al.  Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. , 2002, Diabetes.

[22]  P. Schling,et al.  Effects of Angiotensin II on Adipose Conversion and Expression of Genes of the Renin-Angiotensin System in Human Preadipocytes , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[23]  M. Katovich,et al.  Effects of inhibition of the renin‐angiotensin system on the cardiovascular actions of insulin , 2000, Diabetes, obesity & metabolism.

[24]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[25]  T. Buchanan,et al.  TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. , 1998, Controlled clinical trials.

[26]  L. Velloso,et al.  Effect of Captopril, Losartan, and Bradykinin on Early Steps of Insulin Action , 1997, Diabetes.

[27]  C. Glass,et al.  Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors , 1997, Molecular and cellular biology.

[28]  R. Simsolo,et al.  The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. , 1995, The Journal of clinical investigation.

[29]  C. Darimont,et al.  Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. , 1994, Endocrinology.

[30]  Arya M. Sharma,et al.  Influences of AT1 receptor blockade on tissue metabolism in obese men. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[31]  T. Iwasaka,et al.  Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. , 2006, Thrombosis research.

[32]  L. Scott,et al.  Eprosartan: a review of its use in the management of hypertension. , 2005, Drugs.

[33]  B. Spiegelman,et al.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. , 1999, Molecular cell.